Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080626 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00080626 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 19 participants.
The verdict
NCT00080626, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well neoadjuvant docetaxel works in treating women who are undergoing surgery for breast cancer.
Interventions
- DRUG docetaxel
- PROCEDURE conventional surgery
- BIOLOGICAL pegfilgrastim
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2003-08-11 |
| Est. Completion | 2006-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00080626
The ClinicalTrials.gov registry entry for NCT00080626 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which docetaxel is the first listed.
NCT00080626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00080626 about?
NCT00080626 is a clinical study titled "Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well neoadjuvant doc...
What is the current status of trial NCT00080626?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2003-08-11. Estimated completion is 2006-05-01.
What interventions are being tested in trial NCT00080626?
The interventions under investigation include: docetaxel (DRUG), conventional surgery (PROCEDURE), pegfilgrastim (BIOLOGICAL), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00080626?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.